A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®
NCT ID: NCT00532922
Last Updated: 2009-06-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
310 participants
OBSERVATIONAL
2007-04-30
2007-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma
NCT00573222
Real Life Effectiveness in Patients With Not Optimally Controlled Asthma
NCT00784953
Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever Therapy
NCT01711840
Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation
NCT01232335
Study to Investigate the Efficacy of Symbicort® SMART.
NCT00839800
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Chinese asthma patient prescribed Symbicort® Turbuhaler®
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Asthmatics who has been prescribed Symbicort according to physician's judgement
3. Usage of Symbicort should follow local prescribing information
Exclusion Criteria
2. No previous enrolment in the present study
6 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhou Xin
Role: PRINCIPAL_INVESTIGATOR
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hong Jianguo
Role: PRINCIPAL_INVESTIGATOR
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Hefel, Anhui, China
Research Site
Fuzhou, Fujian, China
Research Site
Guangzhou, Guangdong, China
Research Site
Shenzhen, Guangdong, China
Research Site
Zhengzhou, Henan, China
Research Site
Wuhan, Hubei, China
Research Site
Wuhan, Hubel, China
Research Site
Nanjong, Jiangsu, China
Research Site
Suzhou, Jiangsu, China
Research Site
Shenyand, Liaoning, China
Research Site
Qingdao, Shandong, China
Research Site
Taiyuan, Shanxi, China
Research Site
Xi’an, Shanxi, China
Research Site
Chengdu, Sichuan, China
Research Site
Wenzhou, Zhejiang, China
Research Site
Beijing, , China
Research Site
Chongqing, , China
Research Site
Hangzhou, , China
Research Site
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-RCN-SYM-2006/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.